Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402W6 | ISIN: US5019761049 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
3,270 US-Dollar
-5,76 % -0,200
1-Jahres-Chart
KYVERNA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KYVERNA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur KYVERNA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.06.Kyverna Therapeutics, Inc. - 8-K, Current Report9
27.05.With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?4
14.05.Kyverna Therapeutics GAAP EPS of -$1.032
14.05.Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace4
13.05.Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results69Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA)...
► Artikel lesen
27.03.Kyverna Therapeutics files for $250M mixed securities shelf4
27.03.Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results997Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration...
► Artikel lesen
KYVERNA THERAPEUTICS Aktie jetzt für 0€ handeln
27.03.Kyverna Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.03.Kyverna Therapeutics, Inc. - 10-K, Annual Report3
27.03.Kyverna Therapeutics, Inc. - 8-K, Current Report1
22.01.Kyverna Therapeutics Appoints Naji Gehchan as Chief Medical & Development Officer5
21.01.Kyverna Therapeutics Names Naji Gehchan Chief Medical And Development Officer-
21.01.Kyverna Therapeutics appoints new chief medical officer1
21.01.Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer252Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to...
► Artikel lesen
21.01.Kyverna Therapeutics, Inc. - 8-K, Current Report-
13.01.Kyverna Therapeutics, Inc. - 8-K, Current Report1
13.12.24Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth239Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna)...
► Artikel lesen
14.11.24Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024208Positive Sustained Efficacy and Durability at>6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment...
► Artikel lesen
13.11.24Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results210Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance...
► Artikel lesen
12.08.24Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results161Actively recruiting clinical trials in neurology and rheumatology with KYV-101 No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 Received FDA RMAT Designation...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1